

## Amoéba: Deferral of the 4th tranche of OCAs

**Chassieu (France), January 7th, 2021 - 5:45 p.m. - AMOÉBA (FR0011051598 - ALMIB)**, producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and of a biocontrol product for plant protection, still in the development phase, informs that it has exercised the suspension option relating to the issue of the 4th tranche of OCAs.

In accordance with article 3.1.3 of the contract for the issuance of bonds convertible into shares signed with Nice & Green SA on December 17, 2020<sup>1</sup>, Amoéba has **decided to exercise the suspension option relating to the issuance of the 4th tranche of 60 bonds**. According to the terms of the contract, this suspension can be exercised for a maximum period of 2 months. The exercise of the suspension option results in the automatic postponement of the issuance of the suspended tranche immediately after the suspension period and the commitment period is extended for a maximum period equal to the suspension phase.

### **About AMOÉBA:**

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection estimated globally at €1.6Bn (4). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (3) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on Euronext Growth. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on [www.amoeba-nature.com](http://www.amoeba-nature.com).

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets

(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

### **Contacts:**

#### **Amoéba**

Valérie FILIATRE

Directeur Général Adjoint

+33 4 26 69 16 00

[v.filiatre@amoeba-nature.com](mailto:v.filiatre@amoeba-nature.com)

#### **Calyptus**

Relations investisseurs & Presse

Grégory BOSSON / Mathieu CALLEUX

+33 1 53 65 37 90 /91

[amoeba@calyptus.net](mailto:amoeba@calyptus.net)

<sup>1</sup> See Press release of December 17, 2020

**Disclaimer**

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the Universal Registration Document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 12, 2021 under number D21-0289 (a copy of which is available on [www.amoeba-biocide.com](http://www.amoeba-biocide.com)). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.